Skip to content
Medical Health Aged Care

Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced Drug Product Manufacturing Facility from Catalent

Ardena Holding NV. 3 mins read

Ghent, Belgium, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands and Sweden, today announced it has signed a definitive agreement to acquire Catalent’s state-of-the-art facility in Somerset, New Jersey. This acquisition will significantly enhance Ardena’s capabilities in downstream late-stage and small-scale commercial manufacturing of oral drug products, supporting its strategy to become a leading global CDMO offering integrated solutions across the entire pharmaceutical development lifecycle.

The FDA-approved Somerset facility employs approximately 200 skilled scientists and technicians and is a Center of Excellence for advanced delivery of oral dosage forms, complementing Ardena’s existing oral solid expertise. This acquisition also positions Ardena well to expand its bioanalytical services in the US to serve a growing client base driven by an ever-increasing demand for advanced drug development services. The facility's specialized technologies and analytical capabilities bolster Ardena’s integrated offering, providing comprehensive solutions for pharmaceutical and biotechnology customers on both sides of the Atlantic.

"Today marks a significant milestone in Ardena’s international growth strategy," explains Jeremie Trochu, Chief Executive Officer of Ardena. "We are thrilled to welcome the talented scientific and operations team from Somerset into the Ardena family. Their commitment to providing exceptional service aligns perfectly with our core values of excellence, reliability, care, and integrity. Together, we will continue to support biopharma companies at the cutting edge of innovation to deliver life-changing therapies to patients worldwide."

"This expansion into North America is pivotal for Ardena as we continue to broaden our global footprint," said Mr. Trochu. "By adding advanced technologies such as Hot Melt Extrusion, we are not only enhancing our bioavailability improvement solutions but also aligning with our expertise in developing innovative nanomedicine drug delivery systems. This investment accelerates our scale of operations and breadth of offerings to better serve our fast-growing international client base."

GHO Capital, Ardena’s private equity partner, has been instrumental in facilitating this acquisition as part of their ongoing commitment to accelerate Ardena’s transatlantic expansion. The Partners at GHO Capital, commented, "We are excited to see this high-impact acquisition come to fruition. It significantly enhances Ardena’s technological and market capabilities across key regions, positioning the company for sustained value creation and long-term success under Jeremie’s leadership."

The transaction is expected to close in early 2025, subject to regulatory approvals and other customary closing conditions.

Notes to Editors:

About Ardena

Ardena is a leading Contract Development and Manufacturing Organization in advanced drug development of new, innovative, and complex molecules. Ardena’s mission is to enable current and next-generation therapies to get into the clinic and to patients faster.

Ardena assists biopharmaceutical companies in navigating through the drug discovery and development process to create effective and compliant drug substances and products for clinical trials, by providing integrated services including solid state chemistry, API, and nanomedicine development and manufacturing, analytical and formulation development, drug product manufacturing, bioanalytical and CMC regulatory services.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1be1c9c2-0305-4238-b377-4e11a264d6d8


For more information, please contact:
Manuel Leal
Corporate Marketing Director
marketing@ardena.com
www.ardena.com

Primary Logo

More from this category

  • Medical Health Aged Care
  • 06/11/2024
  • 01:12
BeiGene, Ltd.

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

Five-year results of Phase 3 SEQUOIA study demonstrate durable benefits of BRUKINSA in patients with CLL Two oral presentations showcase promising safety and efficacy…

  • Contains:
  • Medical Health Aged Care, National News Current Affairs
  • 05/11/2024
  • 16:17
National Rural Health Alliance

Unleashing the potential of the rural and remote health workforce

The long-awaited final report Unleashing the Potential of our Health Workforce: Scope of Practice Review was released today following over a year long process to conduct the review in four phases. “The National Rural Health Alliance congratulates the team led by Professor Mark Cormack for this important review which will provide the direction for health policy for many years to come,” said Susi Tegen, Chief Executive of the National Rural Health Alliance. “We are particularly pleased to see the focus on rural and remote barriers highlighted and solutions.” The report provides a number of specific inclusions and recommendations related to…

  • Contains:
  • Medical Health Aged Care
  • 05/11/2024
  • 14:35
Royal Australian College of GPs

GPs warn of worse access and more waste under Scope of Practice recommendations

The Royal Australian College of GPs (RACGP) has urged the Federal Government to exercise caution in its assessment of the recommendations of the Scope of Practice Review report, warning some recommendations will make seeing a GP harder for more patients. The College said some of the report’s recommendations may sound good on the surface but will result in a costlier health system, more delays to care, and higher out-of-pocket costs for patients. The RACGP is particularly concerned about the proposal to open direct referral pathways to more health professionals. RACGP President Dr Nicole Higgins said: “This is a report, not…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.